Profound Medical Corp. (TSX: PRN)
Canada
· Delayed Price · Currency is CAD 10.61
+0.06 (0.57%)
Nov 22, 2024, 3:59 PM EST
Profound Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1.38 | 0.39 | 2 | 3.15 | 4.58 | 4.17 | Upgrade
|
| Other Revenue | 7.6 | 6.81 | 4.68 | 3.72 | 2.72 | - | Upgrade
|
| Revenue | 8.98 | 7.2 | 6.68 | 6.87 | 7.3 | 4.17 | Upgrade
|
| Revenue Growth (YoY) | 39.35% | 7.75% | -2.79% | -5.90% | 74.99% | 60.40% | Upgrade
|
| Cost of Revenue | 3.41 | 2.82 | 3.66 | 3.92 | 3.83 | 1.78 | Upgrade
|
| Gross Profit | 5.57 | 4.38 | 3.02 | 2.95 | 3.47 | 2.39 | Upgrade
|
| Selling, General & Admin | 22.41 | 18.62 | 17.93 | 17.97 | 12.43 | 7.9 | Upgrade
|
| Research & Development | 16.25 | 14.38 | 14.69 | 15.28 | 9.91 | 9.4 | Upgrade
|
| Operating Expenses | 38.66 | 33 | 32.62 | 33.24 | 22.34 | 17.29 | Upgrade
|
| Operating Income | -33.09 | -28.62 | -29.6 | -30.29 | -18.86 | -14.9 | Upgrade
|
| Interest Expense | -0.68 | -0.77 | -0.17 | -0.07 | -0.54 | -1.04 | Upgrade
|
| Interest & Investment Income | 1.91 | 1.64 | 0.8 | 0.21 | 0.69 | 0.36 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.61 | -0.58 | 3.1 | -0.29 | -2.54 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.15 | -0.38 | 0.02 | -0.16 | -0.24 | -0.12 | Upgrade
|
| EBT Excluding Unusual Items | -31.38 | -28.7 | -25.86 | -30.59 | -21.49 | -15.7 | Upgrade
|
| Impairment of Goodwill | - | - | -2.52 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.09 | 0.62 | Upgrade
|
| Pretax Income | -31.38 | -28.7 | -28.38 | -30.59 | -21.58 | -15.08 | Upgrade
|
| Income Tax Expense | 0.01 | -0.13 | 0.29 | 0.11 | 0.05 | 0.15 | Upgrade
|
| Net Income | -31.39 | -28.57 | -28.67 | -30.7 | -21.62 | -15.22 | Upgrade
|
| Net Income to Common | -31.39 | -28.57 | -28.67 | -30.7 | -21.62 | -15.22 | Upgrade
|
| Shares Outstanding (Basic) | 24 | 21 | 21 | 20 | 17 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 21 | 21 | 20 | 17 | 11 | Upgrade
|
| Shares Change (YoY) | 12.36% | 1.69% | 1.79% | 18.33% | 55.83% | 10.55% | Upgrade
|
| EPS (Basic) | -1.33 | -1.35 | -1.38 | -1.50 | -1.25 | -1.37 | Upgrade
|
| EPS (Diluted) | -1.33 | -1.35 | -1.38 | -1.50 | -1.25 | -1.37 | Upgrade
|
| Free Cash Flow | -24.83 | -22.3 | -25.8 | -22.39 | -20.57 | -15.05 | Upgrade
|
| Free Cash Flow Per Share | -1.05 | -1.05 | -1.24 | -1.09 | -1.19 | -1.36 | Upgrade
|
| Gross Margin | 62.02% | 60.87% | 45.22% | 42.95% | 47.56% | 57.26% | Upgrade
|
| Operating Margin | -368.27% | -397.50% | -443.08% | -440.72% | -258.26% | -357.07% | Upgrade
|
| Profit Margin | -349.41% | -396.85% | -429.11% | -446.66% | -296.03% | -364.69% | Upgrade
|
| Free Cash Flow Margin | -276.36% | -309.72% | -386.17% | -325.80% | -281.68% | -360.57% | Upgrade
|
| EBITDA | -32.46 | -27.87 | -28.83 | -29.61 | -18.36 | -14.37 | Upgrade
|
| EBITDA Margin | - | - | - | - | -251.34% | - | Upgrade
|
| D&A For EBITDA | 0.63 | 0.75 | 0.78 | 0.68 | 0.51 | 0.53 | Upgrade
|
| EBIT | -33.09 | -28.62 | -29.6 | -30.29 | -18.86 | -14.9 | Upgrade
|
| EBIT Margin | - | - | - | - | -258.26% | - | Upgrade
|
| Revenue as Reported | 8.98 | 7.2 | 6.68 | 6.87 | 7.3 | 4.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.